UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of a class molecules exhibiting both microbiological and immunomodulatory effects. UNION is focused on the treatment of inflammatory skin disease, but the chemistry platform and its versatile mode of action is widely applicable across a wide range of diseases.

From an investment perspective, UNION represents a multi-pronged opportunity with several products in clinical development for treatment of microbiome and inflammatory diseases - and a number of qualified follow-on preclinical and discovery programs. The company has raised funds through The European Investment Bank as well as private investors and non-dilutive sources to reach the current stage of development.

For more information, please contact:
+45 2381 5487